PMID- 31652460
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20200915
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 39
IP  - 10
DP  - 2019 Oct 30
TI  - Engineering anti-cancer nanovaccine based on antigen cross-presentation.
LID - 10.1042/BSR20193220 [doi]
LID - BSR20193220
AB  - Dendritic cells (DCs) present exogenous antigens on major histocompatibility 
      complex (MHC) class I molecules, thereby activating CD8+ T cells, contributing to 
      tumor elimination through a mechanism known as antigen cross-presentation. A 
      variety of factors such as maturation state of DCs, co-stimulatory signals, 
      T-cell microenvironment, antigen internalization routes and adjuvants regulate 
      the process of DC-mediated antigen cross-presentation. Recently, the development 
      of successful cancer immunotherapies may be attributed to the ability of DCs to 
      cross-present tumor antigens. In this review article, we focus on the underlying 
      mechanism of antigen cross-presentation and ways to improve antigen 
      cross-presentation in different DC subsets. We have critically summarized the 
      recent developments in the generation of novel nanovaccines for robust CD8+ 
      T-cell response in cancer. In this context, we have reviewed nanocarriers that 
      have been used for cancer immunotherapeutics based on antigen cross-presentation 
      mechanism. Additionally, we have also expressed our views on the future 
      applications of this mechanism in curing cancer.
CI  - (c) 2019 The Author(s).
FAU - Warrier, Vaishnavi U
AU  - Warrier VU
AD  - Protein Biochemistry Research Laboratory, Dr. D.Y. Patil Biotechnology and 
      Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth (Deemed to be University), 
      Tathawade, Pune 411033, Maharashtra, India.
FAU - Makandar, Amina I
AU  - Makandar AI
AD  - Protein Biochemistry Research Laboratory, Dr. D.Y. Patil Biotechnology and 
      Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth (Deemed to be University), 
      Tathawade, Pune 411033, Maharashtra, India.
FAU - Garg, Manoj
AU  - Garg M
AD  - Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity 
      University, Noida 201313, Uttar Pradesh, India.
FAU - Sethi, Gautam
AU  - Sethi G
AD  - Department of Pharmacology, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore 117600, Singapore.
FAU - Kant, Ravi
AU  - Kant R
AD  - Experimental Neuroimmunology, Klinikum rechts der Isar, Technical University of 
      Munich, Munich, Germany.
FAU - Pal, Jayanta K
AU  - Pal JK
AD  - Protein Biochemistry Research Laboratory, Dr. D.Y. Patil Biotechnology and 
      Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth (Deemed to be University), 
      Tathawade, Pune 411033, Maharashtra, India.
FAU - Yuba, Eiji
AU  - Yuba E
AD  - Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture 
      University, 1-1 Gakuen-cho, Naka-ku, Sakai 599-8531, Osaka, Japan.
FAU - Gupta, Rajesh Kumar
AU  - Gupta RK
AD  - Protein Biochemistry Research Laboratory, Dr. D.Y. Patil Biotechnology and 
      Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth (Deemed to be University), 
      Tathawade, Pune 411033, Maharashtra, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - *Antigen Presentation
MH  - Antigens, Neoplasm/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cancer Vaccines/*immunology
MH  - *Cross-Priming
MH  - Humans
MH  - *Neoplasms/immunology/pathology/therapy
MH  - Tumor Microenvironment/*immunology
PMC - PMC6822533
OTO - NOTNLM
OT  - Antigen Cross-presentation
OT  - Cancer immunotherapy
OT  - DC-SIGN
OT  - Dendritic cell (DC)
OT  - Glycan
OT  - Nanocarriers
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2019/10/28 06:00
MHDA- 2020/09/17 06:00
PMCR- 2019/10/18
CRDT- 2019/10/26 06:00
PHST- 2019/09/10 00:00 [received]
PHST- 2019/09/27 00:00 [revised]
PHST- 2019/10/01 00:00 [accepted]
PHST- 2019/10/26 06:00 [entrez]
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2019/10/18 00:00 [pmc-release]
AID - 220729 [pii]
AID - BSR20193220 [pii]
AID - 10.1042/BSR20193220 [doi]
PST - ppublish
SO  - Biosci Rep. 2019 Oct 30;39(10):BSR20193220. doi: 10.1042/BSR20193220.